SG11201602501VA - Hiv treatment formulation of atazanavir and cobicistat - Google Patents

Hiv treatment formulation of atazanavir and cobicistat

Info

Publication number: SG11201602501VA
Authority: SG; Singapore
Prior art keywords: cobicistat; atazanavir; treatment formulation; hiv treatment; hiv
Prior art date: 2013-10-07

Application number

SG11201602501VA

Other languages

English (en)

Inventor

Otilia May Yue Koo

Faranak Nikfar

Jing Tao

Niranjan Kumar Kottala

Sailesh A Varia

Original Assignee

Bristol Myers Squibb Holdings Ireland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-07

Filing date

2014-10-06

Publication date

2016-04-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51743576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201602501V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-10-06 Application filed by Bristol Myers Squibb Holdings Ireland filed Critical Bristol Myers Squibb Holdings Ireland

2016-04-28 Publication of SG11201602501VA publication Critical patent/SG11201602501VA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SG11201602501VA 2013-10-07 2014-10-06 Hiv treatment formulation of atazanavir and cobicistat SG11201602501VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361887574P	2013-10-07	2013-10-07
PCT/US2014/059310 WO2015054133A1 (en)	2013-10-07	2014-10-06	Hiv treatment formulation of atazanavir and cobicistat

Publications (1)

Publication Number	Publication Date
SG11201602501VA true SG11201602501VA (en)	2016-04-28

Family

ID=51743576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201602501VA SG11201602501VA (en)	2013-10-07	2014-10-06	Hiv treatment formulation of atazanavir and cobicistat

Country Status (28)

Country	Link
US (2)	US20160038502A1 (he)
EP (2)	EP3054926B1 (he)
JP (2)	JP6574415B2 (he)
KR (1)	KR102286386B1 (he)
CN (1)	CN106029058A (he)
AU (1)	AU2014332200B2 (he)
BR (1)	BR112016007526A8 (he)
CA (1)	CA2926650A1 (he)
CL (1)	CL2016000787A1 (he)
CY (1)	CY1121105T1 (he)
DK (2)	DK3054926T3 (he)
EA (1)	EA031172B1 (he)
ES (2)	ES2927484T3 (he)
HR (2)	HRP20221126T1 (he)
HU (1)	HUE059757T2 (he)
IL (1)	IL244881B (he)
LT (2)	LT3421033T (he)
MX (1)	MX368268B (he)
MY (1)	MY178960A (he)
PE (1)	PE20160596A1 (he)
PL (2)	PL3421033T3 (he)
PT (2)	PT3421033T (he)
RS (2)	RS57882B1 (he)
SA (1)	SA516370891B1 (he)
SG (1)	SG11201602501VA (he)
SI (2)	SI3054926T1 (he)
SM (2)	SMT201800507T1 (he)
WO (1)	WO2015054133A1 (he)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2582877T3 (es) *	2010-04-09	2016-09-15	Bristol-Myers Squibb Holdings Ireland	Formulaciones de sulfato de atazanavir con un efecto de pH mejorado
KR20240162560A (ko)	2015-10-30	2024-11-15	캔서 프리벤션 파마수티컬스, 인코포레이티드	에플로르니틴 및 설린닥, 고정된 용량 조합 제제
CA2937365C (en)	2016-03-29	2018-09-18	F. Hoffmann-La Roche Ag	Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
ES2952878T3 (es) *	2016-08-08	2023-11-06	Hetero Labs Ltd	Una composición antirretroviral multiclase
EP3496718A4 (en)	2016-08-08	2020-01-22	Hetero Labs Limited	ANTIRETROVIRAL COMPOSITIONS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5558071A (en) *	1994-03-07	1996-09-24	Combustion Electromagnetics, Inc.	Ignition system power converter and controller
US5849911A (en)	1996-04-22	1998-12-15	Novartis Finance Corporation	Antivirally active heterocyclic azahexane derivatives
IL134830A0 (en) *	2000-03-01	2001-05-20	Chay 13 Medical Res Group N V	Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
JP2003526671A (ja) *	2000-03-14	2003-09-09	レストラゲン，インコーポレイテッド	幽門洞−十二指腸運動性に対するグルカゴン様ペプチド‐１（７−３６）の作用
US8461129B2 (en) *	2006-09-25	2013-06-11	Archer Daniels Midland Company	Superabsorbent surface-treated carboxyalkylated polysaccharides and process for producing same
LT2487166T (lt)	2007-02-23	2016-11-10	Gilead Sciences, Inc.	Terapinių agentų farmakokinetinių savybių moduliatoriai
CN101801348A (zh) *	2007-06-22	2010-08-11	百时美施贵宝公司	含有阿扎那韦的压片组合物
US20130084243A1 (en) *	2010-01-27	2013-04-04	Liliane Goetsch	Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
WO2009084036A2 (en) *	2007-12-20	2009-07-09	Matrix Laboratories Limited	Composition for treatment of viral infections
AU2009296734B2 (en) *	2008-09-25	2016-02-18	Cephalon Llc	Liquid formulations of bendamustine
US20110028412A1 (en) *	2009-08-03	2011-02-03	Cappellos, Inc.	Herbal enhanced analgesic formulations
ES2582877T3 (es) *	2010-04-09	2016-09-15	Bristol-Myers Squibb Holdings Ireland	Formulaciones de sulfato de atazanavir con un efecto de pH mejorado

2014
- 2014-10-06 CN CN201480066184.XA patent/CN106029058A/zh active Pending
- 2014-10-06 SI SI201430857T patent/SI3054926T1/sl unknown
- 2014-10-06 PT PT181797960T patent/PT3421033T/pt unknown
- 2014-10-06 WO PCT/US2014/059310 patent/WO2015054133A1/en active Application Filing
- 2014-10-06 SM SM20180507T patent/SMT201800507T1/it unknown
- 2014-10-06 CA CA2926650A patent/CA2926650A1/en not_active Abandoned
- 2014-10-06 MY MYPI2016701258A patent/MY178960A/en unknown
- 2014-10-06 LT LTEP18179796.0T patent/LT3421033T/lt unknown
- 2014-10-06 PE PE2016000463A patent/PE20160596A1/es unknown
- 2014-10-06 ES ES18179796T patent/ES2927484T3/es active Active
- 2014-10-06 PL PL18179796.0T patent/PL3421033T3/pl unknown
- 2014-10-06 HU HUE18179796A patent/HUE059757T2/hu unknown
- 2014-10-06 SM SM20220373T patent/SMT202200373T1/it unknown
- 2014-10-06 PL PL14786421T patent/PL3054926T3/pl unknown
- 2014-10-06 HR HRP20221126TT patent/HRP20221126T1/hr unknown
- 2014-10-06 EA EA201690594A patent/EA031172B1/ru not_active IP Right Cessation
- 2014-10-06 AU AU2014332200A patent/AU2014332200B2/en active Active
- 2014-10-06 KR KR1020167011723A patent/KR102286386B1/ko active Active
- 2014-10-06 RS RS20181143A patent/RS57882B1/sr unknown
- 2014-10-06 DK DK14786421.9T patent/DK3054926T3/en active
- 2014-10-06 BR BR112016007526A patent/BR112016007526A8/pt not_active Application Discontinuation
- 2014-10-06 EP EP14786421.9A patent/EP3054926B1/en active Active
- 2014-10-06 LT LTEP14786421.9T patent/LT3054926T/lt unknown
- 2014-10-06 RS RS20220859A patent/RS63570B1/sr unknown
- 2014-10-06 EP EP18179796.0A patent/EP3421033B1/en active Active
- 2014-10-06 MX MX2016004078A patent/MX368268B/es active IP Right Grant
- 2014-10-06 DK DK18179796.0T patent/DK3421033T3/da active
- 2014-10-06 ES ES14786421.9T patent/ES2693580T3/es active Active
- 2014-10-06 PT PT14786421T patent/PT3054926T/pt unknown
- 2014-10-06 JP JP2016520670A patent/JP6574415B2/ja active Active
- 2014-10-06 US US14/425,443 patent/US20160038502A1/en not_active Abandoned
- 2014-10-06 SI SI201431985T patent/SI3421033T1/sl unknown
- 2014-10-06 SG SG11201602501VA patent/SG11201602501VA/en unknown
2016
- 2016-04-04 IL IL244881A patent/IL244881B/he unknown
- 2016-04-05 CL CL2016000787A patent/CL2016000787A1/es unknown
- 2016-04-07 SA SA516370891A patent/SA516370891B1/ar unknown
2018
- 2018-08-30 JP JP2018161767A patent/JP2019011334A/ja active Pending
- 2018-10-03 HR HRP20181582TT patent/HRP20181582T1/hr unknown
- 2018-10-18 CY CY181101050T patent/CY1121105T1/el unknown
2019
- 2019-08-07 US US16/534,263 patent/US20190358240A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CL2016000787A1 (es)	2016-11-25
US20160038502A1 (en)	2016-02-11
PE20160596A1 (es)	2016-06-15
CY1121105T1 (el)	2019-12-11
AU2014332200A1 (en)	2016-05-19
DK3054926T3 (en)	2018-10-29
MX368268B (es)	2019-09-26
PT3421033T (pt)	2022-09-23
DK3421033T3 (da)	2022-10-10
PT3054926T (pt)	2018-10-26
EP3054926A1 (en)	2016-08-17
JP2019011334A (ja)	2019-01-24
EP3421033B1 (en)	2022-07-27
HRP20221126T1 (hr)	2022-11-25
HRP20181582T1 (hr)	2018-11-30
RS57882B1 (sr)	2019-01-31
MX2016004078A (es)	2016-06-06
EP3421033A1 (en)	2019-01-02
SMT202200373T1 (it)	2022-11-18
KR20160060764A (ko)	2016-05-30
JP2016532649A (ja)	2016-10-20
EP3054926B1 (en)	2018-07-25
ES2693580T3 (es)	2018-12-12
SA516370891B1 (ar)	2018-08-08
WO2015054133A1 (en)	2015-04-16
ES2927484T3 (es)	2022-11-07
CN106029058A (zh)	2016-10-12
IL244881B (he)	2021-12-01
SMT201800507T1 (it)	2018-11-09
HUE059757T2 (hu)	2023-01-28
EA031172B1 (ru)	2018-11-30
AU2014332200B2 (en)	2018-10-04
SI3054926T1 (sl)	2018-10-30
BR112016007526A2 (pt)	2017-08-01
KR102286386B1 (ko)	2021-08-05
CA2926650A1 (en)	2015-04-16
EA201690594A1 (ru)	2016-09-30
RS63570B1 (sr)	2022-10-31
IL244881A0 (he)	2016-05-31
PL3054926T3 (pl)	2018-12-31
MY178960A (en)	2020-10-26
LT3421033T (lt)	2022-11-10
US20190358240A1 (en)	2019-11-28
JP6574415B2 (ja)	2019-09-11
PL3421033T3 (pl)	2022-10-03
BR112016007526A8 (pt)	2020-03-03
SI3421033T1 (sl)	2022-11-30
LT3054926T (lt)	2018-11-12

Publication	Publication Date	Title
ZA201601344B (en)	2017-05-31	Methods and compositions for rna-guided treatment of hiv infection
HK1246296A1 (zh)	2018-09-07	多環氨基甲酰基吡啶酮化合物和其用於治療hiv感染的用途
HK1223615A1 (zh)	2017-08-04	多環氨基甲酰基吡啶酮化合物和其用於治療感染的用途
HK1221416A1 (zh)	2017-06-02	氧雜雙環庚烷和氧雜雙環庚烯的配製品
HRP20181582T1 (hr)	2018-11-30	Formulacija atazanavira i kobicistata za liječenje hiv-a
HK1223855A1 (zh)	2017-08-11	拉喹莫德和氟吡汀組合物用於治療多發性硬化症
EP2968127A4 (en)	2016-09-07	LOW GLYCEROL PREPARATIONS FOR HIV TREATMENT AND PREVENTION
PL3166642T3 (pl)	2020-11-30	Transdermalne preparaty pergolidu i ich zastosowanie
AU2013101402A4 (en)	2013-12-05	Timber treatment formulations and methods of use